


Amendments to the Claims

Claim 1 (currently amended): A compound which is represented by comprising formula (I) below



(I)

wherein

R₁ is CH₃ or CH₂CH₃;

R₂ is a *para* and/or *meta* substituted phenyl group;

R₃ is H, CH₃ or CH₂CH₃; and

R₄ is a linear or cyclic aliphatic group, which is optionally substituted,
or, wherein

R₁ and R₂ are as stated above while R₃ and R₄ are parts of a 4- to 6-membered cyclic entity, which is optionally substituted,

and which compound has affinity for human IgG of κ-type.

Claim 2 (currently amended): A compound according to The compound of claim 1, which is an affinity ligand with affinity for the constant region of a Fab fragment of human IgG of κ-type.

Claim 3 (currently amended): A compound according to The compound of claim 1 or 2, wherein R₁ is CH₃.

Claim 4 (currently amended): ~~A compound according to any one of the preceding claims, wherein R₂ comprises is a substituted phenyl group and the having substituents are selected from the group that consists consisting of F, Cl, Br, I and O.~~

Claim 5 (currently amended): ~~A compound according to any one of the preceding claims, The compound of claim 1,~~ wherein the phenyl group of R₂ is substituted in the *para* position with a group ~~defined as~~ -O-R₅, wherein R₅ is either CH₃ or CH₂CH₃.

Claim 6 (currently amended): ~~A compound according to any one of the preceding claims, The compound of claim 4,~~ wherein the phenyl group of R₂ is substituted with Cl or F in the *meta* position.

Claim 7 (currently amended): ~~A compound according to any one of claims 1-4, The compound of claim 4,~~ wherein the phenyl group of R₂ is substituted with Cl in *meta* and *para* position.

Claim 8 (currently amended): ~~A compound according to any one of the preceding claims, The compound of claim 1,~~ wherein R₄ is an aliphatic group, which includes oxygen atoms in one or more positions ~~is interrupted in one or more positions by oxygen atoms.~~

Claim 9 (currently amended): ~~A compound according to any one of the preceding claims, The compound of claim 1,~~ wherein R₄ is an aliphatic group, which ~~comprises~~ contains one or more carbonyl group groups.

Claim 10 (currently amended): ~~A compound according to any one of the preceding claims, The compound of claim 1,~~ wherein R₄ is an aliphatic group ~~that comprises which includes~~ a terminating functionality selected from the group ~~that consists consisting~~ of a carboxylic acid, nitrogen, oxygen, sulphur or any derivative thereof.

Claim 11 (currently amended): ~~A compound according to any one of the preceding claims, The compound of claim 1,~~ wherein R₁ is CH₃; R₂ is a phenyl group that has been substituted with Cl in *meta* and *para* position; and R₃ and R₄ are parts of a cyclic 5-membered group, ~~which is optionally substituted~~.

Claim 12 (currently amended): ~~A compound according to The compound of claim 11,~~ wherein the cyclic 5-membered entity is substituted in a position directly adjacent to N with a C(O)-O-CH₃ group.

Claim 13 (currently amended): ~~A compound according to any one of the preceding claims, The compound of claim 1,~~ which is capable of binding ~~human~~ to the constant region of a human IgG of κ-type, or a functional derivative thereof, with a binding constant of at least 10⁻³ M.

Claim 14 (currently amended): ~~A compound according to any one of the preceding claims, The compound of claim 1,~~ which is capable of binding to the constant region of a human IgG of κ-type, or a functional derivative thereof, via a binding pocket defined by the structure coordinates of the amino acids as shown in Fig 6.

Claim 15 (cancelled)

Claim 16 (currently amended): A sorption complex ~~comprised of a compound according to any one of claims 1-14 comprising the compound of claim 1~~ directly linked to the constant region of a Fab fragment of a human IgG of κ-type, or a functional derivative thereof.

Claim 17 (currently amended): A separation matrix for affinity chromatography, ~~which matrix comprises comprising~~ ligands coupled to a support, wherein the majority of the ligands are ~~the compounds of claim 1 as defined in any one of claims 1-14.~~

Claim 18 (currently amended): ~~A-The~~ separation matrix ~~according to~~ of claim 17, wherein the ligands have been coupled to the support via linkers.

Claim 19 (currently amended): ~~A-The~~ separation matrix ~~according to~~ of claim 17-~~or 18~~, wherein the support is a porous polymeric particle.

Claim 20 (cancelled)

Claim 21 (currently amended): A system suitable for affinity chromatography, ~~which is comprised of a separation matrix as defined in any one of claims 17-19 comprising the separation matrix of claim 17 packed in a column.~~